Mechanisms of Action of Atypical Antipsychotics

CNS Spectrums

Volumn 10, Issue S10, 2005, Pages 5-11

  Cañas, Fernando ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745075136     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900025165     Document Type: Article

References (42)

1. 2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000; 25: 161–166.
2. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49: 538–544.
3. 1 values. J Pharmacol Exp Ther. 1989; 251: 238–246.
4. Andreasen, NC, Black, DW. Introductory Textbook of Psychiatry. 3rd ed. Washington, DC: American Psychiatric Press; 2001; 204–228.
5. Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001; 158: 176–184.
6. Ananth, J, Parameswaran, S, Hara, B. Drug therapy in schizophrenia. Curr Pharm Des. 2004; 10: 2205–2217.
7. Sedvall, G, Farde, L. Chemical brain anatomy in schizophrenia. Lancet. 1995; 346: 743–749.
8. Seeman, P, Chau-Wong, M, Tedesco, J, Wong, K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A. 1975; 72: 4376–4380.
9. Sesack, SR, Carr, DB. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav. 2002; 77: 513–517.
10. Nyberg, S, Eriksson, B, Oxenstiema, G, Halldin, C, Farde, L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999; 156: 869–875.
11. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993; 33: 227–235.
12. 2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology (Berl). 1996; 124: 285–287.
13. 2 receptors. Proc Natl Acad Sci USA. 2000; 97: 7673–7675.
14. Seeman, P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol. 1988; 8(suppl):S3–S9.
15. Huttunen, M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol. 1995; 15(suppl):S4–S10.
16. 1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol. 2004; 18: 346–354.
17. 1A receptor binding in amygdala of schizophrenia. Biol Psychiatry. 2004; 55: 439–444.
18. Meltzer, HY, Matsubara, S, Lee, JC. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989; 25: 390–392.
19. Goyer, PF, Berridge, MS, Morris, ED, et al. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med. 1996; 37: 1122–1127.
20. Meltzer, HY. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bull. 1991; 2: 263–287.
21. Crook, JM, Tomaskovic-Crook, E, Copolov, DL, Dean, B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry. 2000; 48: 381–388.
22. Dean, B, Crook, JM, Opeskin, K, Hill, C, Keks, N, Copolov, DL. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry. 1996; 1: 54–58.
23. 1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia [Letter]. Neuropsychopharmacology. 2004; 29: 1583–1584.
24. Kafka, MS, van Kammen, DP. alpha-Adrenergic receptor function in schizophrenia: receptor number, cyclic adenosine monophosphate production, adenylate cyclase activity, and effect of drugs. Arch Gen Psychiatry. 1983; 40: 264–270.
25. Kalkman, HO, Loetscher, E. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol. 2003; 462: 33–40.
26. Iversen, PL, Cornish, KG, Iversen, LJ, Mata, JE, Bylund, DB. Bolus intravenous injection of phosphorothioate oligonudeotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists. Toxicol Appl Pharmacol. 1999; 160: 289–296.
27. 1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol. 1991; 104: 270–276.
28. 2C receptor agonist, in Zucker rats. Brain Res. 2004; 1011: 221–227.
29. Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychophormacology. 2003; 28: 519–526.
30. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988; 45: 71–76.
31. Baron, JC, Martinot, JL, Cambon, H, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychophormacology (Berl). 1989; 99: 463–472.
32. Smith, M, Wolf, AP, Btodie, JD, et al. Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry. 1988; 23: 653–663.
33. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004; 161: 818–825.
34. Leysen, JE, Gommeren, W, Eens, A, de Courcelles, D, Stoof, JC, Janssen, PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988; 247: 661–670.
35. 2 antagonistic properties. J Pharmacol Exp Ther. 1988; 244: 685–693.
36. Bymaster, FP, Calligaro, DO, Falcone, JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychophormacology. 1996; 14: 87–96.
37. Nemeroff, CB, Kinkead, B, Goldstein, J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002; 63(suppl 13):5–11.
38. Hirose, T, Uwahodo, Y, Yamada, S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 20O4; 18: 375–383.
39. 2 receptot antagonistic activity. J Pharmacol Exp Ther. 1995; 274: 329–336.
40. Carnahan, RM, Lund, BC, Perry, PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy. 2001; 21: 717–730.
41. Purdon, SE, Jones, BD, Stip, E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000; 57: 249–258.
42. Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychophormacology. 1999; 20: 491–505.